Skip to main content
Top
Published in: PharmacoEconomics 4/2014

01-04-2014 | Letter to the Editor

Capturing Disutility from Waiting Time

Author: Afschin Gandjour

Published in: PharmacoEconomics | Issue 4/2014

Login to get access

Excerpt

In many industrialized and developing countries, waiting times for medical tests and procedures are a major public concern. Hence, process disutility resulting from waiting times deserves to be considered in resource allocation decisions. The review by Brennan and Dixon [1] on the methods and results of incorporating process (dis)utility in quality-adjusted life-years (QALYs) is therefore a much welcomed and timely contribution.1 Yet, in my opinion it is important to consider where process disutility from waiting time is coming from as it affects the type of elicitation procedure to be recommended. Process disutility associated with waiting times can be divided into two distinct sources: impatience and anxiety. Other sources of disutility from waiting time exist (e.g. stress and fatigue) but are associated both with impatience and anxiety. That is, they do not represent a distinct category. But waiting time may also cause a utility gain because some individuals may feel positive tension and hope (e.g. when a procedure is expected to provide relief). …
Footnotes
1
The review also considers process (dis)utility from drug delivery methods and dosing strategies, and therefore is broader in scope. Still, as shown in Tables 3 and 4, roughly half of the studies included in the review address process (dis)utility from waiting time.
 
Literature
1.
go back to reference Brennan VK, Dixon S. Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics. 2013;31(8):677–91.PubMedCrossRef Brennan VK, Dixon S. Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics. 2013;31(8):677–91.PubMedCrossRef
2.
go back to reference Howard K, Salkeld G, McCaffery K, Irwig L. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? Health Econ. 2008;17(5):593–605.PubMedCrossRef Howard K, Salkeld G, McCaffery K, Irwig L. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? Health Econ. 2008;17(5):593–605.PubMedCrossRef
3.
go back to reference Gandjour A. Incorporating feelings related to the uncertainty about future health in utility measurement. Health Econ. 2008;17(10):1207–13.PubMedCrossRef Gandjour A. Incorporating feelings related to the uncertainty about future health in utility measurement. Health Econ. 2008;17(10):1207–13.PubMedCrossRef
4.
go back to reference Johannesson M. The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty. Int J Technol Assessm Health Care. 1995;11(1):40–8.CrossRef Johannesson M. The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty. Int J Technol Assessm Health Care. 1995;11(1):40–8.CrossRef
5.
go back to reference Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989;9(2):142–9.PubMedCrossRef Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989;9(2):142–9.PubMedCrossRef
6.
go back to reference Mehrez A, Gafni A. The healthy-years equivalents: how to measure them using the standard gamble approach. Med Decis Making. 1991;11(2):140–6.PubMedCrossRef Mehrez A, Gafni A. The healthy-years equivalents: how to measure them using the standard gamble approach. Med Decis Making. 1991;11(2):140–6.PubMedCrossRef
7.
go back to reference Mehrez A, Gafni A. Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs). Pharmacoeconomics. 1992;1(5):338–45.PubMedCrossRef Mehrez A, Gafni A. Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs). Pharmacoeconomics. 1992;1(5):338–45.PubMedCrossRef
8.
go back to reference Johnson FR, Hauber AB, Ozdemir S. Using conjoint analysis to estimate healthy-year equivalents for acute conditions: an application to vasomotor symptoms. Value Health. 2009;12(1):146–52.PubMedCrossRef Johnson FR, Hauber AB, Ozdemir S. Using conjoint analysis to estimate healthy-year equivalents for acute conditions: an application to vasomotor symptoms. Value Health. 2009;12(1):146–52.PubMedCrossRef
9.
go back to reference Towers I, Spencer A, Brazier J. Healthy year equivalents versus quality-adjusted life years: the debate continues. Exp Rev Pharmacoecon Outcomes Res. 2005;5(3):245–54.CrossRef Towers I, Spencer A, Brazier J. Healthy year equivalents versus quality-adjusted life years: the debate continues. Exp Rev Pharmacoecon Outcomes Res. 2005;5(3):245–54.CrossRef
10.
go back to reference Levine MN, Gafni A, Markham B, MacFarlane D. A bedside decision instrument to elicit a patient’s preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 1992;117(1):53–8.PubMedCrossRef Levine MN, Gafni A, Markham B, MacFarlane D. A bedside decision instrument to elicit a patient’s preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 1992;117(1):53–8.PubMedCrossRef
Metadata
Title
Capturing Disutility from Waiting Time
Author
Afschin Gandjour
Publication date
01-04-2014
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 4/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-014-0129-y

Other articles of this Issue 4/2014

PharmacoEconomics 4/2014 Go to the issue